论文部分内容阅读
目的:探讨吡格列酮治疗对2型糖尿病合并代谢综合征患者血糖、胰岛素抵抗和炎症因子的影响。方法:回顾性分析我院2013年8月-2015年2月收治的96例2型糖尿病合并代谢综合征患者病例资料,根据治疗方法的不同分为观察组和对照组,每组48例,两组患者均给予糖尿病常规基础治疗,在此基础上,观察组患者给予吡格列酮治疗,治疗3个月。检测治疗前后血糖指标包括空腹血糖(FPG)、餐后2小时血糖(2h PG)以及糖化血糖蛋白(Hb A1c),胰岛素抵抗指标包括空腹胰岛素(FINS)和胰岛素抵抗指数(HOMA-IR)和炎症因子包括超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)。结果:观察组治疗后FPG、2 h PG、Hb A1c分别为(6.19±2.24)mmol/L、(8.30±2.48)mmol/L和(6.01±1.23)%,均显著低于治疗前和对照组治疗后,差异有统计学意义(P<0.05);观察组治疗后FINS和HOMA-IR分别为(6.60±1.92)m IU/L和2.08±1.00,均较治疗前和对照组治疗后显著降低,差异有统计学意义(P<0.05);观察组治疗后hs-CRP、IL-6和TNF-α分别为(6.12±1.67)ng/L、(62.65±10.30)ng/L和(83.16±16.55)ng/L,均较治疗前和对照组治疗后显著降低,差异有统计学意义(P<0.05)。结论:吡格列酮治疗可以显著降低2型糖尿病合并代谢综合征患者血糖水平,改善胰岛素抵抗,降低炎症反应,值得进一步研究。
Objective: To investigate the effects of pioglitazone on blood glucose, insulin resistance and inflammatory factors in type 2 diabetic patients with metabolic syndrome. Methods: A retrospective analysis of 96 cases of type 2 diabetes mellitus patients with metabolic syndrome admitted from August 2013 to February 2015 in our hospital was divided into observation group and control group according to the different treatment methods. Each group had 48 cases and two All patients were given routine basic diabetes treatment. On this basis, patients in observation group were treated with pioglitazone for 3 months. The levels of fasting blood glucose (FPG), 2-hour postprandial blood glucose (2h PG) and glycosylated hemoglobin (Hb A1c) were measured before and after treatment. The indicators of insulin resistance included fasting insulin (FINS) and insulin resistance index Factors include hs-CRP, IL-6 and TNF-α. Results: The FPG, 2 h PG and Hb A1c in the observation group were (6.19 ± 2.24) mmol / L and (8.30 ± 2.48) mmol / L and (6.01 ± 1.23)%, respectively, After treatment, the difference was statistically significant (P <0.05). The FINS and HOMA-IR in the observation group were (6.60 ± 1.92) m IU / L and 2.08 ± 1.00, respectively, which were significantly lower than those before treatment and those in the control group (P <0.05). The levels of hs-CRP, IL-6 and TNF-α in the observation group were (6.12 ± 1.67) ng / L, (62.65 ± 10.30) ng / L and 16.55) ng / L, which were significantly lower than those before treatment and those in the control group after treatment (P <0.05). Conclusion: Pioglitazone treatment can significantly reduce blood glucose levels, improve insulin resistance and reduce inflammation in patients with type 2 diabetes mellitus and metabolic syndrome, which deserves further study.